Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02522767 · ClinicalTrials.gov registry record · Phase 3
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
NCT02522767 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 228 participants.
The verdict
NCT02522767, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
Study Summary
The purpose of this trial is to investigate the efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC. Subject will receive 4 g extended release granules (sachet) once daily.
Interventions
- DRUG Placebo
- DRUG Mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02522767
The ClinicalTrials.gov registry entry for NCT02522767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02522767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02522767 about?
NCT02522767 is a clinical study titled "Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)". The purpose of this trial is to investigate the efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC. Subject will receive 4 g extended release granules (sachet) once daily.
What is the current status of trial NCT02522767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2015-10. Estimated completion is 2018-04-03.
What interventions are being tested in trial NCT02522767?
The interventions under investigation include: Placebo (DRUG), Mesalamine (DRUG).
Who is sponsoring clinical trial NCT02522767?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.